3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
2
Phase NA
1
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Neoplasms
4
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Glioblastoma
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Burkitt Lymphoma
2
Breast Neoplasms
2
Advanced Solid Tumor
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Testicular Neoplasms
1
Spinal Cord Neoplasms
1
Spinal Cord Compression
1
Primary Myelofibrosis
1
Peripheral Lung Tumor
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Melanoma
1
Interventions
pembrolizumab
59
Gemcitabine
37
Biopsy
33
Specimen Handling
32
Paclitaxel
30
Magnetic Resonance Spectroscopy
30
Nivolumab
29
Cisplatin
26
Carboplatin
25
Irinotecan
24
Cyclophosphamide
23
Fluorouracil
22
Bevacizumab
22
Docetaxel
21
Oxaliplatin
19
Leucovorin
18
Ipilimumab
17
Cetuximab
17
Capecitabine
17
130-nm albumin-bound paclitaxel
16
Everolimus
15
Albumin-Bound Paclitaxel
15
Trastuzumab
13
olaparib
12
Pemetrexed
12
Erlotinib Hydrochloride
12
spartalizumab
11
Sorafenib
11
Radiosurgery
11
trastuzumab deruxtecan
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neoplasm Metastasis
×
Therapeutics
×
Clear all
NCT05904236
2025-04-08
ICVB-1042
IconOVir Bio
Phase 1
Terminated
17 enrolled